CIZ

Cizzle Biotechnology Holdings PLC

Health Care First-pass screen £11m

280/1000 Overall fit

AI beneficiary 35% 28

Operating leverage 25% 40

Valuation 25% 22

Downside protection 15% 18

First-pass take

Pre-revenue biotech company with CIZ1B lung cancer diagnostic in early commercialization through single North American partner (royalties only: £525k received by June 2025). Loss-making (£368k H1 2025), negative equity (£(276)k), minimal cash (£182k) with ~3-4 month burn runway.

Flags

loss-makingnegative-equitypre-revenuecash-runway-concernsingle-partner-concentrationearly-stage-biotechmicro-capnot-ai-beneficiary